Research Partnership publishes new patient Living with Atopic Dermatitis (EU) 2019 report
Living with Atopic Dermatitis (AD) is a new quantitative study conducted amongst 403 adults living with the disease and 141 caregivers of children with AD in France, Germany, Italy, Spain and UK.
Intellus Worldwide Summit round up 2019
This May, Liza Pliss, Director and Head of our New York Office, Sabera Hyderally, Director, Head of MedTech Division North America and Emily Hoffman, Associate Director exhibited at and attended the Intellus Worldwide Summit in Philadelphia.
China in the fast lane: Access opportunities for novel therapies in the world's hottest emerging market
In our latest article for pharmaphorum's Deep Dive magazine, Brett Gardiner and Boon Yap discuss access opportunities for novel therapies in the world’s hottest emerging market.
The sheer size of China’s population (1.4 billion) has long made it an attractive market for pharma in terms of potential volume, especially in the context of rising affluence associated with a growing middle class. In 2017, China was ranked the second largest pharmaceutical market in the world, behind the US. However, it has traditionally been a challenging market to launch into, particularly for manufacturers developing innovative and novel therapies. Recent changes to China’s regulations under its 2025 Made in China strategic plan – including an expedited market access process, more frequent updates to Reimbursed Drugs Listings and additional routes to reimbursement – look set to transform this paradigm and necessitate a reconsideration of manufacturers’ strategies to obtaining optimal pricing and reimbursement (P&R).
How Paediatricians and GPs revealed key insights to help develop a science story for a child nutritional supplement
Our client needed to develop a science story in order to increase uptake for their child nutritional supplement. Research was required in order to define the patient target, frame the challenge of growth delays to be an effective call to action, articulate objectives for the product and the best way to express its value proposition.
Research Partnership and Janssen awarded runner-up in the EphMRA MR Excellence Awards
We are delighted to announce that an entry submitted by Janssen and Research Partnership for the 2019 EphMRA MR Excellence Awards has been awarded runner-up in the ‘Business Impact through Innovation’ category.
The category, sponsored by Adelphi, is awarded for demonstrating innovation, which has had a real and significant business impact. The joint submission ‘Using facial analysis to uncover deeper reactions to pharmaceutical communication materials’ demonstrated how Research Partnership and Janssen used one of the latest innovations in healthcare market research, facial analysis, to gain a detailed understanding of physicians’ emotional reactions to an e-detail aid.